Expression of chemokine receptors in angiosarcoma

  • Tomoo Kishi Department of Dermatology, Wakayama Medical University, Wakayama, Japan. Department of Dermatology, Kainan Municipal Medical Center, Kainan, Japan.
  • Yuki Yamamoto Department of Dermatology, Wakayama Medical University, Wakayama, Japan.
  • Chikako Kaminaka Department of Dermatology, Wakayama Medical University, Wakayama, Japan.
  • Seiko Toyozawa Department of Dermatology, Wakayama Medical University, Wakayama, Japan.
  • Hiroshi Matsunaka Department of Dermatology, Wakayama Medical University, Wakayama, Japan.
  • Fukumi Furukawa Department of Dermatology, Wakayama Medical University, Wakayama, Japan.
DOI: https://doi.org/10.18282/jsd.v7.i1.127
Keywords: CXCR4, chemokine receptor, angiosarcoma, immunohistochemistry

Abstract

Angiosarcoma is a rapidly progressing malignant skin tumor associated with a poor prognosis. We report an immunohistochemical investigation of chemokine receptors in angiosarcoma. The aim is to investigate chemokine receptor expression and, if it is expressed, to histologically discuss its association with age, sex, development site, and histological type. Analyzed were 12 angiosarcoma samples (mean patient age: 75.7 years old) collected by biopsy or surgery from patients at our department by comparing with 4 granuloma telangiectaticum samples (mean patient age: 37.5 years old) and 16 healthy skin samples as controls. CXCR4, CCR6, CCR7, and SDF-1 expressions were immunohistochemically investigated. CXCR4 expression was positive in 6 of the 12 samples. CCR6 and CCR7 were negative in all samples. SDF-1 was positive in 4 samples. Out of the 6 CXCR4-positive samples, 4 were SDF-1-positive. No significant difference associated with age, sex, development site, or histological type was noted in the expression of CXCR4, CCR6, CCR7, or SDF-1. Although CXCR4 is regarded as an index of tumor aggressiveness of malignant melanoma, it is suggested that chemokine receptors, such as CXCR4, do not serve as useful markers of angiosarcoma.

References

Griffiths C, Barker J, Bleiker T, Chalmers R, Creamer D (editors). Rook’s textbook of dermatology. 9th ed. Oxford, UK: Wiley-Blackwell; 2016. p. 137.36-38.

Zlotnik A. Chemokines and cancer. Int J Cancer 2006; 119(9); 2026–2029. doi: 10.1002/ijc.22024.

Müller A, Homey B, Soto H, Ge N, Catron D, et al. Involvement of chemokine receptor in breast cancer metastasis. Nature 2001; 410(6824): 50–56. doi: 10.1038/35 065016.

Scala S, Ottaiano A, Ascierto PA, Cavalli M, Simeone E, et al. Expression of CXCR4 predicts poor prognosis in patients with malignant melanoma. Clin Cancer Res 2005; 11(5): 1835–1841. doi: 10.1158/1078-0432.CCR-04-18 87.

Muller A, Sonkoly E, Eulert C, Gerber PA, Kubitza R, et al. Chemokine receptors in head and neck cancer: Association with metastatic spread and regulation during chemotherapy. Int J Cancer 2006; 118(9): 2147–2157. doi: 10.1002/ijc.21514.

Feng LY, Ou ZL, Wu FY, Shen ZZ, Shao ZM. Involvement of a novel chemokine decoy receptor CCX-CKR in breast cancer growth, metastasis and patient survival. Clin Cancer Res 2009; 15(9): 2962–2970. doi: 10.1158/1078-0432.CCR-08-2495.

Wang J, Xi L, Hunt JL, Gooding W, Whiteside TL, et al. Expression pattern of chemokine receptor 6 (CCR6) and CCR7 in squamous cell carcinoma of the head and neck identifies a novel metastatic phenotype. Cancer Res 2004; 64(5): 1861–1866. doi: 10.1158/0008-5472.CAN-03-29 68.

Toyozawa S, Yamamoto Y, Ishida Y, Kondo T, Nakamura Y, et al. Immunohistochemical analysis of CXCR4 expression in fibrohistiocytic tumors. Acta Histochem Cy-tochem 2010; 43(2): 45–50. doi: 10.1267/ahc.10003.

Toyozawa S, Kaminaka C, Furukawa F, Nakamura Y, Matsunaka H, et al. Chemokine receptor CXCR4 is a novel marker for the progression of cutaneous malignant melanomas. Acta Histochem Cytochem 2012; 45(5): 293–299. doi: 10.1267/ahc.12004.

Nakatsugawa S. 舌扁平上皮癌におけるSDF-1/CXCR4 発現と臨床病理的因子との関連について(Japanese) [On the relationship between SDF-1/CXCR4 expression and clinicopathological factors in squamous cell carcinoma of the tongue]. Dokkyo J Med Sci 2012; 39(1): T1–T11.

Elder DE. In: Elenitsas R, Johnson Jr BL, Murphy GF, Xu X, (editors). Lever’s histopathology of the skin. 10th ed. Philadelphia: Lippincott Williams and Wilkins; 2009. p. 1040–1043.

Kaminaka T, Toyozawa S, Yoshi Y, Kunimoto K, Furukawa F, et al. フェノールによる日光角化症とボーエン病の治療効果とケモカインレセプターに関する免疫組織化学的検討 (Japanese) [Phenol peels for the treatment of actinic keratosis and Bowen’s disease: Correlation with chemokine receptors expression]. Skin Cancer 2011; 26(3): 327–332. doi: 10.5227/skincanc er.26.327.

Published
2021-08-21
Issue
Vol. 7 No. 1 (2022)
Section
Original Research Articles

Copyright (c) 2022 Kishi, et al.

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

Author(s) shall retain the copyright of their work and grant the Journal/Publisher rights for the first publication with the work concurrently licensed under the Creative Commons Attribution-Noncommercial 4.0 International License

Under this license, author(s) will allow third parties to download, reuse, reprint, modify, distribute and/or copy the content under the condition that the authors are given credit and that the work is not used for commercial purposes. No permission is required from the authors or the publisher.

This broad license intends to facilitate free access, as well as the unrestricted use of original works of all types. This ensures that the published work is freely and openly available in perpetuity.